Roger Tung, Concert Pharmaceuticals CEO
August 1, 2022 10:22 AM EDTUpdated 05:42 PM
R&D

Pos­i­tive PhI­II re­sults in hand, Con­cert Phar­ma forges ahead with NDA and com­mer­cial­iza­tion plans for hair loss drug

Tyler Patchen

News Reporter

Con­cert Phar­ma­ceu­ti­cals has been wait­ing to tout Phase III da­ta amidst a sell-off of the bulk of its pipeline to Ter­ran Bio­sciences and sev­er­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times